Exact Sciences Stock Fair Value Calculation – Exact Sciences Schedules Q2 2023 Earnings Call to Report on Cancer Screening and Diagnostics Progress
July 13, 2023
🌧️Trending News
EXACT SCIENCES ($NASDAQ:EXAS) Corporation is a global leader in cancer screening and diagnostics. The company is dedicated to improving the lives of cancer patients by providing high-quality, reliable, and accurate test results. The company’s breakthrough technologies have enabled them to expand their reach beyond traditional markets and into new avenues of diagnostics and personalized medicine. EXACT SCIENCES’ innovative approach to cancer screening and diagnostics has led to the development of revolutionary new tests and treatments that promise to revolutionize the way cancer is diagnosed and treated. The call will provide investors with an update on EXACT SCIENCES’ progress in the second quarter of 2023.
Additionally, it will provide information on the company’s financial performance, including its revenue, profitability, and other key metrics. The earnings call will also allow investors to gain insight into the company’s strategy for the upcoming year and its plans for the future. By participating in the earnings call, investors will have the opportunity to hear first-hand from executives about the progress the company has made in cancer screening and diagnostics. This will enable them to make informed decisions about their investments in EXACT SCIENCES and how best to leverage the company’s assets for their own benefit.
Earnings
In the earning report of FY2023 Q1 ending March 31 2021, EXACT SCIENCES earned 402.08M USD in total revenue, but lost 31.16M USD in net income. This represents a 17.4% decrease in total revenue compared to the same time period of the previous year. In the last three years, EXACT SCIENCES’ total revenue has increased to 602.45M USD. The earnings call will provide insight into how their cancer screening and diagnostics have performed during the quarter and what can be expected in the coming quarter.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exact Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 2.2k | -516.72 | -22.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exact Sciences. More…
| Operations | Investing | Financing |
| -88.02 | 111.45 | 207.35 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exact Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.3k | 3.25k | 17 |
Key Ratios Snapshot
Some of the financial key ratios for Exact Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 27.5% | – | -23.1% |
| FCF Margin | ROE | ROA |
| -13.6% | -10.4% | -5.0% |
Market Price
On Tuesday, shares of Exact Sciences opened at $94.7, and closed at $95.3, up 0.4% from the previous closing price of 94.9. This news was met with optimism by investors and analysts alike, who are eager to learn more about the company’s progress in cancer screening and diagnostics. With the upcoming earnings call, Exact Sciences is expected to offer an in-depth look into their strategy and plans for the future. Investors will be paying close attention to how the company’s plans will lead to increased profits and shareholder value. Live Quote…
Analysis – Exact Sciences Stock Fair Value Calculation
GoodWhale is proud to offer valuable financial analysis of EXACT SCIENCES. We employ a proprietary Valuation Line which utilizes metrics such as revenue, earnings, and cash flow to give an accurate and fair estimate of a stock’s worth. After crunching the numbers, we have determined that the fair value of EXACT SCIENCES’ share is around $99.3. At present, EXACT SCIENCES stock is traded at $95.3, which is slightly below the fair value, representing a 4.0% undervaluation. As such, this provides an excellent opportunity for investors who are looking to purchase the stock at a discounted price. We believe that investing in EXACT SCIENCES now will prove to be a wise decision in the future, providing solid returns for our investors. More…
Peers
The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.
Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.
– Myriad Genetics Inc ($NASDAQ:MYGN)
Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.
Summary
Exact Sciences is a leading provider of cancer screening and diagnostic tests, and is a strong option for investors looking to gain exposure to the burgeoning biotechnology sector. The company posted strong growth in the first quarter of 2023, and is expected to report increased revenue and profits in the second quarter as well. The company has a robust balance sheet, and is continuing to invest in new products and technologies that should help drive future growth.
